Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $278000.0.

  • TScan Therapeutics' Other Non-Current Liabilities rose 9041.1% to $278000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278000.0, marking a year-over-year increase of 9041.1%. This contributed to the annual value of $135000.0 for FY2024, which is N/A changed from last year.
  • Per TScan Therapeutics' latest filing, its Other Non-Current Liabilities stood at $278000.0 for Q3 2025, which was up 9041.1% from $113000.0 recorded in Q2 2025.
  • TScan Therapeutics' Other Non-Current Liabilities' 5-year high stood at $278000.0 during Q3 2025, with a 5-year trough of $12000.0 in Q3 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $97000.0 (2021), whereas its average is $118600.0.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 8762.89% in 2023, then skyrocketed by 111666.67% in 2024.
  • TScan Therapeutics' Other Non-Current Liabilities (Quarter) stood at $97000.0 in 2021, then plummeted by 49.48% to $49000.0 in 2022, then tumbled by 75.51% to $12000.0 in 2023, then skyrocketed by 1025.0% to $135000.0 in 2024, then surged by 105.93% to $278000.0 in 2025.
  • Its Other Non-Current Liabilities was $278000.0 in Q3 2025, compared to $113000.0 in Q2 2025 and $124000.0 in Q1 2025.